Accordingly, Zhang et al (2002) showed that monoclonal anti-VEGFR2 antibody treatment of RMS xenografts led only to minor effects on tumour growth and angiogenesis, but when combined with low-dose, doxorubicin results in full responsiveness and complete remission. This evidence concerns the gene KDR and neoplasm.